Abstract: The invention provides formulations containing highly concentrated solutions of rifabutin and methods of making such formulations. The invention also provides methods of using such formulations to treat a bacterial infection in a subject.

Abstract: The invention provides systems and methods for increased clinical efficacy of rifabutin against A. baumannii. The invention takes advantage of the discovery of a ferric-coprogen (FhuE) receptor that is responsible for the uptake of rifabutin into A. baumannii cells. Methods preferably include obtaining a sample from a patient suspected of having an infection; performing a test on the sample to identify an infection of A. baumannii in the patient; and providing a formulation of rifabutin for treating the patient that, when administered to the patient, maximizes a resultant AUC and/or Cmax. The method may include administering the formulation of rifabutin to the patient. Preferably the formulation is delivered to the patient, e.g., by intravenous injection and results in a Cmax is that greater than about 2 mg/L and optionally less than about 50 mg/L.

Abstract: The invention provides antibiotic combination therapies for treating an A. baumannii infection in a subject. The combination therapies include rifabutin and a second antibiotic, such as colistin and cefiderocol.

Abstract: The invention provides systems and methods for increased clinical efficacy of rifabutin against A. baumannii. The invention takes advantage of the discovery of a ferric-coprogen (FhuE) receptor that is responsible for the uptake of rifabutin into A. baumannii cells. Methods preferably include obtaining a sample from a patient suspected of having an infection; performing a test on the sample to identify an infection of A. baumannii in the patient; and providing a formulation of rifabutin for treating the patient that, when administered to the patient, maximizes a resultant AUC and/or Cmax. The method may include administering the formulation of rifabutin to the patient. Preferably the formulation is delivered to the patient, e.g., by intravenous injection and results in a Cmax is that greater than about 2 mg/L and optionally less than about 50 mg/L.

Abstract: The invention provides antibiotic combination therapies for treating an A. baumannii infection in a subject. The combination therapies include rifabutin and a member of the polymyxin class of antibiotics, such as commercially available natural products antibiotics, e.g., polymyxins B and polymyxins E (colistin and its pro-drug colistin methane sulfonate (CMS)) and synthetic or semi-synthetic derivatives and analogs, e.g., SPR206, MRX-8 and QPX9003 and polymyxin-like antibiotics, e.g.

Abstract: The invention provides antibiotic combination therapies for treating an A. baumannii infection in a subject. The combination therapies include rifabutin and a second antibiotic, such as colistin and cefiderocol.

Abstract: The invention provides systems and methods for increased clinical efficacy of rifabutin against A. baumannii. The invention takes advantage of the discovery of a ferric-coprogen (FhuE) receptor that is responsible for the uptake of rifabutin into A. baumannii cells. Methods preferably include obtaining a sample from a patient suspected of having an infection; performing a test on the sample to identify an infection of A. baumannii in the patient; and providing a formulation of rifabutin for treating the patient that, when administered to the patient, maximizes a resultant AUC and/or Cmax. The method may include administering the formulation of rifabutin to the patient. Preferably the formulation is delivered to the patient, e.g., by intravenous injection and results in a Cmax is that greater than about 2 mg/L and optionally less than about 50 mg/L.

Abstract: The invention provides formulations containing highly concentrated solutions of rifabutin and methods of making such formulations. The invention also provides methods of using such formulations to treat a bacterial infection in a subject.

Abstract: The invention provides antibiotic combination therapies for treating an A. baumannii infection in a subject. The combination therapies include rifabutin and a second antibiotic, such as colistin and cefiderocol.

Abstract: The invention provides systems and methods for increased clinical efficacy of rifabutin against A. baumannii. The invention takes advantage of the discovery of a ferric-coprogen (FhuE) receptor that is responsible for the uptake of rifabutin into A. baumannii cells. Methods preferably include obtaining a sample from a patient suspected of having an infection; performing a test on the sample to identify an infection of A. baumannii in the patient; and providing a formulation of rifabutin for treating the patient that, when administered to the patient, maximizes a resultant AUC and/or Cmax. The method may include administering the formulation of rifabutin to the patient. Preferably the formulation is delivered to the patient, e.g., by intravenous injection and results in a Cmax is that greater than about 2 mg/L and optionally less than about 50 mg/L.

Abstract: The invention provides formulations containing highly concentrated solutions of rifabutin and methods of making such formulations. The invention also provides methods of using such formulations to treat a bacterial infection in a subject.

Abstract: The present invention relates to a compound according to formula (I), wherein R1 and R5 are independently selected from H, halogen, hydroxyl, NO2, CN, C1-C6-alkyl optionally substituted by one or more R11, C1-C6-alkoxy optionally substituted by one or more R11, C3-C6-cycloalkyl optionally substituted by one or more R11, —Cn-alkyl-N(R12)(R13) with n=0-3, —Cn-alkyl-C(O)N(R12)(R13) with n=0-3, —SO2—N(R14)-C(O)—R15; —Cn-alkyl-N(R14)-C(O)—R15 with n=0-3, —Cn-alkyl-C(O)—OR16 with n=0-3, —O(C1-C3-alkyl-O)m—C1-C3-alkyl-OR10 with m=0-3, —Cn-alkyl-OR16 with n=0-3, —NH—Cn-alkyl-R18 with n=0-3; —O—Cn-alkyl-R18 with n=0-3; —OPO(OR10)2, —PO(OR10)2, and a heterocycle optionally substituted by one or more R17; R3 is selected from halogen, hydroxyl, NO2, CN, C1-C6-alkyl optionally substituted by one or more R11, C1-C6-alkoxy optionally substituted by one or more R11, C3-C6-cycloalkyl optionally substituted by one or more R11, —Cn-alkyl-N(R12)(R13) with n=0-3, —Cn-alkyl-C(O)N(R12)(R13) with n=0-3, —SO2—N(R14)-C(O)—R15; —Cn-alk

Abstract: The invention provides antibiotic combination therapies for treating an A. baumannii infection in a subject. The combination therapies include rifabutin and a second antibiotic, such as colistin and cefiderocol.

Abstract: The invention provides formulations containing highly concentrated solutions of rifabutin and methods of making such formulations. The invention also provides methods of using such formulations to treat a bacterial infection in a subject.

Abstract: The invention provides antibiotic combination therapies for treating an A. baumannii infection in a subject. The combination therapies include rifabutin and a second antibiotic, such as colistin and cefiderocol.

Abstract: The invention provides systems and methods for increased clinical efficacy of rifabutin against A. baumannii. The invention takes advantage of the discovery of a ferric-coprogen (FhuE) receptor that is responsible for the uptake of rifabutin into A. baumannii cells. Methods preferably include obtaining a sample from a patient suspected of having an infection; performing a test on the sample to identify an infection of A. baumannii in the patient; and providing a formulation of rifabutin for treating the patient that, when administered to the patient, maximizes a resultant AUC and/or Cmax. The method may include administering the formulation of rifabutin to the patient. Preferably the formulation is delivered to the patient, e.g., by intravenous injection and results in a Cmax is that greater than about 2 mg/L and optionally less than about 50 mg/L.

Abstract: The present invention relates to ketolide compounds of Formula I. The compounds have good anti-microbial activities, reduced inhibition of cytochrome P4503A4 (CYP3A4), and acceptable safety of co-administration of other drugs. The present invention also relates to a pharmaceutical composition comprising compounds of Formula I and the method of treating anti-microbial infection by administering the compounds. Oral administration is a preferred route of administration.

Abstract: Pharmaceutical formulations for treating bacterial or fungal infections comprising iclaprim or its enantiomers and a sulfonamide antibiotic, and treatment and manufacturing methods, kits and dosage forms thereof, are provided.

Abstract: Pharmaceutical formulations for treating bacterial or fungal infections comprising iclaprim or its enantiomers and a sulfonamide antibiotic, and treatment and manufacturing methods, kits and dosage forms thereof, are provided.

Abstract: Template-fixed ?-hairpin peptidomimetics of the general formula (I) wherein Z is a template-fixed chain of 12, 14 or 18 ?-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid), are Gly, NMeGly, Pro or Pip, or of certain types which, as the remaining symbols in the above formula, are defined in the description and the claims, and salts thereof, have CXCR4 antagonizing properties These ?-hairpin peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.